ClinicalTrials.gg
Not yet recruitingNCT06591715Updated Feb 12, 2025

Investigation of Biopsychosocial Characteristics of Individuals with Knee Osteoarthritis

An observational study in Osteoarthritis (OA) of the Knee, sponsored by Aysima Barlak. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-12.

Sponsored by Aysima Barlak · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years and older
Sex
All
01

Study summary

Since pain and depression are observed together in rheumatic diseases, the concept of limitation caused by the disease and health-related quality of life becomes more determinant than radiological joint damage. Sleep problems observed in OA also increase the level of depression findings and difficulty in movement. The chronic nature of the disease includes issues such as pain, fatigue, sleep problems, loss of function, anxiety, depression, and social isolation, together as in other chronic diseases. This complex structure accompanies a picture in which inflammatory processes are triggered.

When the literature is examined, the necessity of evaluation and methods including all these biopsychosocial characteristics of chronic diseases with multifaceted symptoms is emphasized. On the other hand, although it is stated that the common goal of non-pharmacological treatments is to contribute to biopsychosocial improvement in the patient, it is emphasized that evaluations with biopsychosocial content are insufficient. This situation causes the need for scales that provide a holistic assessment of chronic diseases. When the literature, including individuals diagnosed with osteoarthritis, is analyzed, the inadequacy of the studies providing biopsychosocial evaluation draws attention.

02

Conditions studied

  • Osteoarthritis (OA) of the Knee

Keywords

  • osteoarthritis
  • biopsychosocial
  • depression
  • social isolation
  • pain
  • sleep
  • functionality
03

In context

Osteoarthritis

4,445 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's planned enrollment of 100 is close to the median of 100 across 803 observational studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Aysima Barlak is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will consist of individuals who come to the university hospital for routine controls.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of knee osteoarthritis according to ACR knee osteoarthritis diagnostic criteria
  • Being in stage 2 or 3 according to Kellgren-Lawrence radiological staging criteria
  • To be 18 years of age or older
  • Being a reader-writer
  • Having read and signed the informed consent

Exclusion criteria

Exclusion Criteria:

  • History of major psychiatric illness
  • Having malignant disease
  • Having chronic infectious or other rheumatologic diseases
  • Serious knee trauma or surgical operation in the last 6 months
  • Having collagen tissue disease
  • History of peripheral vascular disease or neuropathy
  • Being in stage 4 according to Kellgren Lawrence radiologic staging criteria
  • To have received a physiotherapy program for the relevant knee in the last 3 months
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Interventions

  • OtherHome exercise program

    The home exercise program routinely given to individuals with knee OA in addition to their medical treatment will consist of exercises routinely used in the BETY innovation.

06

What researchers measure

Primary outcomes

  1. Cognitive Exercise Therapy Approach (BETY)- Biopsychosocial Questionnaire

    The BETY Questionnaire was developed on rheumatic patients and was introduced to the literature as a standardized biopsychosocial measurement tool as a result of improving the definitions of recovery from patients with expert opinions and statistical analysis. Scoring of the scale is done using a 5-point Likert system, each item is scored between 0 and 4 points, and a high total score in the scale consisting of a total of 30 items indicates a high biopsychosocial impact.

    Time frame: 3 mounths

Secondary outcomes

  1. Health Asessement Questionnaire (HAQ)

    It is a questionnaire developed in individuals with rheumatoid arthritis and can be used widely and extensively in all rheumatic disease groups and in a wide range of populations including OA. It has 8 subheadings and consists of a total of 20 questions. The sub-headings include dressing, sitting and staying, eating, walking, hygiene, reaching, grasping and activities of daily living. Each answer is scored between 0 and 3 points and the higher the score, the more difficult the activity is.

    Time frame: 3 mounths

  2. Hospital Anxiety Depression Scale (HADS)

    Although the HADS was developed 20 years ago for the clinical measurement of anxiety and depression levels and was originally developed for hospitalized individuals, it now has a wide spectrum of use and can be used in many situations, including healthy people. Seven of the 14 items provide insight into the level of anxiety, while seven include questions about the level of depression. Each question is scored between 0 and 3, with a higher score indicating higher affect. Anxiety and depression sub-parameters are scored separately and a score of 11 and above is considered abnormal.

    Time frame: 3 mounths

  3. Short Form - 36

    SF-36 scale will be used to determine the level of health status and quality of life of individuals.SF-36 is a patient-oriented assessment scale created in the United States of America that allows for general health screening.Each sub-parameter is scored between 0 and 100 points and a high score indicates good health status.The SF-36 scale has 8 sub-parameters including general health perception, physical function, social function, pain, mental health, role difficulties due to physical causes, role difficulties due to emotional causes and vitality and includes 11 questions with a total of 36 items.

    Time frame: 3 mounths

  4. WOMAC Osteoarthritis Index

    The most commonly used disease-specific questionnaire for the assessment of disease severity in hip or knee OA is the WOMAC questionnaire recommended by the Outcome Measures in Rheumatology Clinical Trials. WOMAC assesses pain, endurance and physical functioning, functional status and stiffness. This scale has gained increasing acceptance in the assessment of OA since its introduction in 1986. The pain subscale includes five items asking about pain with activity, at rest and at night. The stiffness heading includes two questions. The functional status heading includes an assessment of difficulty in 17 different activities. The items are scored from 0 to 4 according to difficulty and the degree of pain and stiffness felt, with a higher total score indicating greater severity of the disease.

    Time frame: 3 mounths

  5. Pain Catastrophizing Scale

    This scale, developed by Sullivan et al. (1995), measures the exaggerated negative mental reaction of individuals to current or anticipated painful experiences and the extent to which they catastrophize pain.The reliability and validity of the Turkish version of the scale was demonstrated by Uğurlu et al. (2017) and consists of 13 items.Each item is scored as never=0, slightly=1, moderately=2, greatly=3 and always=4.A high total score indicates a high degree of catastrophizing of pain.

    Time frame: 3 mounths

  6. Tampa Scale of Kinesiophobia

    This scale is a 17-question scale developed to measure fear of movement/reinjury.The scale includes parameters of injury/re-injury and fear-avoidance in work-related activities

    Time frame: 3 mounths

  7. Time Up and Go Test

    The balance status of the individual is evaluated by getting up from a chair with back support, walking 3 meters at a normal walking speed and returning back to the chair and the time he/she sits on the chair is measured and recorded in seconds.The test is repeated 3 times.

    Time frame: 3 mounths

  8. Stair Climb Test

    In measuring the lower extremity strength and dynamic balance of the individual, the time to ascend and descend 10 steps of 16-20 cm stairs with a handrail as fast as possible is recorded in seconds. The test will be repeated 3 times and the times will be recorded.

    Time frame: 3 mounths

  9. 30s Sit to Stand test

    To assess lower limb strength, the subject is asked to stand upright in a chair with arms crossed over the chest and then sit down again. The subject is asked to repeat as quickly as possible for a period of 30 seconds. The score for this assessment test is the number of times the individual stands up fully from a sitting position with arms crossed within 30 seconds.

    Time frame: 3 mounths

  10. 10 m Walk Tets

    The individual is asked to walk quickly but without running on a 10-meter path. Three repetitions of the assessment are recorded in seconds.

    Time frame: 3 mounths

  11. 6 min Walk Test

    It will be used to assess the functional capacity of the patients. Patients will be asked to walk as long as possible in a 20-meter hospital corridor for 6 minutes in their own rhythm and with standard commands and the distance walked will be recorded in meters.

    Time frame: 3 mounths

  12. Muscle Strength

    Muscle strength will be assessed using the Biodex System 3 Pro® isokinetic device (Biodex Medical Systems Inc., Shirley, NY, USA). Before the first assessment, participants will be recruited to a familiarization session. Each assessment will be preceded by a 10-minute warm-up walk and participants will perform knee flexor and extensor maximal concentric isokinetic muscle strength tests at angular velocities of 180°/s (10 repetitions) and 60°/s (5 repetitions) with a 30-second rest interval. Peak torque (PT) and average power (AP) will be recorded in Newtons (Nm) and watts (W) per meter.

    Time frame: 3 mounths

  13. Muscle Endurance

    In order to evaluate muscular endurance, it will be applied with 20 repetitions at 180°/s angular velocity. A rest period of 30 seconds will be given between the tests. Peak torque measurement will be recorded in Newton meters (Nm). Total work during all repetitions will be recorded in Joules (J).

    Time frame: 3 mounths

  14. Proprioception

    To assess knee proprioception, "active position sense" will be measured at 30°, 45° and 60° by the "Biodex System Pro3 Isokinetic System (Biodex Corp. Shirley NY, USA) as recommended in the literature. Deviation from the target angle will be recorded as absolute angular error, regardless of whether the error is negative or positive. The test will be repeated three times. The mean of the patients\' absolute angular errors at each test angle over 3 repetitions will be processed as data

    Time frame: 3 mounths

07

Study locations

1 site
  • Hacettepe University
    Ankara, Altındağ 06100, Turkey (Türkiye)
    • Aysima Barlak, License · Contact · 0-312-305 25 25
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2025; primary completion for Sep 2027, 30 months later.

Of 235 non-industry observational studies under Osteoarthritis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 64. This study's planned 30 months is close to that.

Counting every sponsor, half of 324 studies reached it within 38 months; a quarter within 15 and three quarters within 103.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2024
First posted
Sep 19, 2024
StartEst.
Mar 1, 2025
Primary completionEst.
Sep 9, 2027
CompletionEst.
Sep 9, 2027
Last update
Feb 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06591715
Lead sponsor
Aysima Barlak
Responsible party
Aysima Barlak (PT, Hacettepe University) — Sponsor-investigator
First posted
Sep 19, 2024
Start date
Mar 1, 2025 (estimated)
Primary completion
Sep 9, 2027 (estimated)
Completion
Sep 9, 2027 (estimated)
Last update
Feb 12, 2025

Study contacts

Aysima Barlak, Licence
Contact
fztasyimabarlak@gmail.com
5412311754

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion